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DOI 10.1186/s12944-015-0110-6RESEARCH Open AccessApolipoprotein A5 and apolipoprotein C3
single nucleotide polymorphisms are
correlated with an increased risk of
coronary heart disease: a case–control and
meta-analysis study
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Background: Triglycerides (TGs) are proatherogenic lipoproteins involving the risk of coronary heart disease (CHD),
while apolipoprotein A5 (APOA5) and apolipoprotein C3 (APOC3) are main lipoproteins composing TG-rich
lipoproteins. In this study, we aim to explore the correlation of CHD with APOA5 -1131 T > C and APOC3 -455 T > C
single nucleotide polymorphisms (SNPs).
Methods: A sum of 210 CHD patients, hospitalized between Jan. 2013 and Mar. 2015 at China-Japan Union Hospital,
Jilin University, were selected as our case group and 223 healthy individuals who had physical examination at same
hospital at the same period were selected as control group. The frequency distribution of genotypes of APOA5
-1131 T > C and APOC3 -455 T > C SNPs were measured by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP). The Stata 12.0 software was utilized for statistical analyses.
Results: There was no significant difference on age and sex between case and control group (P > 0.05). History of
smoking, drinking, hypertension and diabetes mellitus, body mass index and levels of TG and fasting blood sugar in
case group were shown to be higher than control group (P < 0.05), while levels of total cholesterol, high-density
lipoprotein cholesterol and low-density lipoprotein cholesterol in case group were lower than control group (P < 0.05).
Both CC and TC′ + CC frequencies of APOA5 -1131 T > C and APOC3 -455 T > C in case group were higher compared to
control group (both P < 0.05). Additionally, T allele frequencies of the two SNPs in case group were lower than control
group, while C allele in case group has higher frequencies compared to control group (both P < 0.05). The results of
meta-analysis under allele and dominant models showed that APOA5 -1131 T > C and APOC3 -455 T > C SNPs are likely
to increase the risk of CHD (both P < 0.05).
Conclusion: APOA5 -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression
of CHD.
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Coronary heart disease (CHD), also known as coronary
atherosclerotic heart disease is a kind of thrombotic
arterial disease, caused by hypoxia and myocardial ische-
mia owing to coronary atherosclerotic mediated vascular
obstruction as well as coronary functional change [1, 2].
CHD has become one of leading diseases threatening
human health and causing mortality, with an estimated
7.2 million individual worldwide die of this disease an-
nually based on the World Health Organization [3]. In
2015, CHD alone caused approximately one of every
seven deaths in the United States, and each year, there
has emerged about 635,000 Americans who have a new
coronary attack [4]. CHD is a complex multifactorial
disorder and both non-genetic and genetic factors can
contribute to the development and progression of this
disease [5]. The non-genetic factors attributed to CHD
has been clearly established, including type 2 diabetes,
obesity, dyslipidemia, hypertension, low-density lipopro-
tein cholesterol (LDL-C), high density lipoprotein chol-
esterol (HDL-C) and lifestyle, such as smoking, lack of
exercise and high fat diet [6, 7]. Interestingly, there is an
inverse relationship between triglyceride (TG) levels and
HDL-C levels, and in metabolic syndrome, high LDL
levels reduce the TG content of HDL, thus reducing the
size of the HDL particle and making it more prone for
renal clearance; besides, excess of TG in the HDL
particle contribute to HDL dysfunction [8]. Circulating
triglyceride-rich lipoproteins from hypertriglyceridemic
subjects mediated endothelial inflammation and drive
monocyte infiltration into the wall of arterial [9]. Although
prime interest was devoted to LDL-C as proatherogenic,
TG are considered in the last years to be also proathero-
genic and some studies provide evidence for causal
involvement of TG-mediated pathways in CHD and the
concentration of it (both fasting and non-fasting) in
prediction of future cardiovascular disease events [9–14].
Apolipoprotein A5 (APOA5) is a fourthly discovered
member of the APOA4/APOC3/APOA1 apolipoprotein
cluster and the human APOA5 gene is located at
chromosome 11q23 [15]. APOA5 gene comprises four
exons and encodes APOA5, a protein of 366 amino
acids, which is an effective stimulator of lipoprotein
lipase and can facilitate lipoprotein remnant clearance
in a LDL receptor-dependent manner [16, 17]. It was
reported that nucleotide sequence variations in the
APOA5 gene have been correlated to high TG levels,
exerting pleiotropic influences on different groups [18].
Apolipoprotein C3 (APOC3) is a significant component
of TG-rich lipoproteins and a minor component of
HDL [19]. APOC3 gene, also located in the chromo-
some 11q23, participates in transport and clearance of
very-low-density lipoprotein (VLDL), chylomicron rem-
nants, and HDL from the bloodstream [20]. APOC3encodes a 79-amino-acid glycoprotein, which was pro-
duced largely in the liver interfering with receptor
induced lipoprotein uptake and inhibiting the activation
of lipoprotein lipase [21]. An increasing number of evi-
dence suggested that APOA5 -1131 T > C and APOC3
-455 T > C single nucleotide polymorphisms (SNPs)
contribute a substantial role in development of CHD
owing to their correlation with increased plasma TGs,
which has become the focus of oversea and domestic
researchers [22, 23]. Nevertheless, there also emerged
contradictory results on the role of APOA5 and
APOC3 variants in CHD [24, 25]. In consideration of
the controversial results from previous studies, we
performed a case–control study to clearly address the
correlation of CHD with APOA5 -1131 T > C and




A total of 210 CHD patients (141 male and 69 female),
hospitalized between Jan. 2013 and Mar. 2015 at
China-Japan Union Hospital, Jilin University, were se-
lected as our case group, among which 70 were acute
myocardial infarction (MI), 109 were angina pectoris
(27 stable, 82 unstable) and 31 were old MI. All CHD
patients aged from 47 to 80 years, with mean age of
62.76 ± 9.98 years, and their diagnoses were based on
American College of Cardiology/American Heart Asso-
ciation (2013) [26]. The diagnosis criteria were at least
one with a diameter stenosis of ≥ 50 % in left main, left
anterior descending, left circumflex and right coronary
arteries, further examined by coronary arteriography
and then evaluated through two interventional cardiol-
ogists. In addition, 223 healthy individuals (139 males
and 84 females) who had physical examination at
China-Japan Union Hospital, Jilin University at the
same period were selected as control group, aged from
46 to 81 years (mean age: 62.44 ± 10.16 years). All sub-
jects in control group had no positive sign, without
history of CHD, cerebrovascular diseases or peripheral
vascular diseases, and they showed normal in routine
screening of blood and urine, chest X-ray, and liver and
kidney function. Subjects included in our study have no
blood relationship each other and we excluded subjects
who had acute inflammation, rheumaimmune systemic
diseases, malignant tumors, liver and renal diseases and
thyroid disease (except hypertension and diabetes melli-
tus), and took lipid-lowering drugs in nearly four
weeks. This study was authorized by the Ethical Com-
mittee of China-Japan Union Hospital, Jilin University,
and all subjects included in our study provided written
informed consent. All procedures in this study were in
compliance with the Declaration of Helsinki [27].
Table 1 Primer sequencing of ApolipoproteinA5 (APOA5) -1131 T > C and apolipoproteinC3 (APOC3) -455 T > C single nucleotide
polymorphisms (SNPs)
SNP Primer Fragment length (bp) Annealing (°C) Cycles
−1131 T > C (rs662799) F: 5′-GATTGATTCAAGATGCATTTAGGAC-3′ 188 59 35
R: 5′-CCCCAGGAACTGGAGCGAAATT-3′
−455 T > C (rs2854116) F: 5′- GCACTCGCCTGCCTGGATT-3′ 413 60 35
R: 5′- TGATGCCACGCTGCTGTCCC-3′
F forward, R reverse, SNP single nucleotide polymorphism
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Peripheral blood (5 ml) was collected from each subject
on an empty stomach for 12 h. OLYMPUS AU640
Analyzer (YZB/JAP 0357) was employed to determine
levels of TG, total cholesterol (TC), HDL-C, LDL-C and
fasting blood sugar (FBS).SNPs detection
APOA5 rs662799 and APOC3 rs2854116 SNPs were se-
lected as our research targets. DNA extraction was
undergone in the silicone membrane genomic DNA
purification kit (Beijing SBS Genetech Co., Ltd.). The
frequency distribution of allele and genotype of different
SNPs in case and control group were measured by
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP). PCR primers were designed
by Primer Premier 5.0 software (PREMIER Biosoft Inter-
national, USA) and synthesized by Beijing Aoke Biotech-
nology Co., Ltd, and amplification site, primer sequence,
fragment length, annealing temperature and number of
cycles were presented in Table 1. For APOA5 -1131 T >
C (rs662799), PCR amplification reaction was performed
in a 20 μl reaction containing DNA 40 ng, 0.2 mol/L of
each forward and reverse primer, 200 μmol/L dATP,
dGTP, dCTP and dTTP, 0.5U Taq DNA polymerase andFig. 1 Gel electrophoresis of apolipoprotein A5 (APOA5) -1131 T > C (rs6627
nucleotide polymorphisms (SNPs) after enzyme digestion (a: -1131 T > C (rsPCR buffer solution. PCR reaction was performed under
the following conditions: predenaturation at 96 °C for
5 min with a total of 35 cycles, denaturation at 96 °C for
45 s, annealing at 59 °C for 30s and elongation at 72 °C
for 45 s, with lastly elongation at 72 °C for 7 min. The
PCR amplification products were allowed to digest with
Mse I restriction enzyme (MBI Company) overnight,
and digestion products were subjected to 10 % polyacryl-
amide gel electrophoresis. The gel was visualized by eth-
idium bromide staining and then photographed under
ultraviolet (UV) light. With regard to APOC3 -455 T > C
(rs2854116), PCR reaction mixture (50 μl) contains 10 ×
buffer 5 μl, dNTP 200 μmol/L, forward primer 25 pmol,
reverse primer 25 pmol, genome DNA 50 ng and Taq
DNA polymerase 0.5 U. After annealing at 60 °C for 30 cy-
cles, 10 μl of PCR amplification products were digested at
37 °C by 8 U BseG I, from which 2 % gel electrophoresis
was utilized to identify genotype, and the results were
examined under UV light and then photographed. Gel
electrophoresis of APOA5 -1131 T > C and APOC3
-455 T > C were shown in Fig. 1a ~ b.Statistical analysis
Data analyses of our case–control study were conducted
using SPSS 18.0 software (IBM Corporation, Somers, NY,99) and apolipoprotein C3 (APOC3) -455 T > C (rs2854116) single
662799) of APOA5; b: -455 T > C (rs2854116) of APOC3)
Table 2 Comparison of clinical data and biochemical index between case and control groups (mean ± standard deviation)
Parameters Case group (n = 210) Control group (n = 223) P
Mean age 62.76 ± 9.98 62.44 ± 10.16 0.7413
Sex (n, %)
M 141 (67.1 %) 139 (62.3 %) 0.2952
F 69 (32.9 %) 84 (37.7 %)
Smoking status (n, %)
Yes 113 (53.8 %) 61 (27.4 %) < 0.0001
No 97 (46.2 %) 162 (72.6 %)
Drinking status (n, %)
Yes 128 (61.0 %) 93 (41.7 %) < 0.0001
No 82 (39.0 %) 130 (58.3 %)
Hypertension status (n, %)
Yes 140 (66.7 %) 70 (31.4 %) < 0.0001
No 70 (33.3 %) 153 (68.6 %)
Diabetes mellitus (n, %)
Yes 36 (17.1 %) 8 (3.6 %) < 0.0001
No 174 (82.9 %) 215 (96.4 %)
TG (mmol/L) 2.41 ± 1.33 1.64 ± 1.00 < 0.0001
TC (mmol/L) 4.74 ± 0.98 5.05 ± 0.89 0.0006
HDL-C (mmol/L) 0.97 ± 0.32 1.33 ± 0.32 < 0.0001
LDL-C (mmol/L) 2.81 ± 0.76 3.07 ± 0.75 0.0004
FBS (mmol/L) 6.30 ± 1.60 5.08 ± 0.62 < 0.0001
BMI (kg/m2) 25.77 ± 3.21 24.29 ± 2.72 < 0.0001
M male, F female, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBS fasting blood
sugar, BMI body mass index
Table 3 Distribution frequencies of genotypes in both apolipoproteinA5 (APOA5) -1131 T > C and apolipoproteinC3 (APOC3) -455 T > C
single nucleotide polymorphisms (SNPs) between case and control groups
SNP Control group (n = 223) Case group (n = 210) P OR 95 % CI
−1131 T > C (rs662799)
TT 96 (43.0 %) 69 (32.9 %) Ref
TC 107 (48.0 %) 101 (48.1 %) 0.194 1.313 0.870 ~ 1.983
CC 20 (9.0 %) 40 (19.0 %) 0.001 2.783 1.497 ~ 5.171
TT 96 (43.0 %) 69 (32.9 %) Ref
TC + CC 127 (57.0 %) 141 (67.1 %) 0.029 1.545 1.044 ~ 2.285
T 299 (67.0 %) 239 (56.9 %) Ref
C 147 (33.0 %) 181 (43.1 %) 0.002 1.54 1.169 ~ 2.031
−455 T > C (rs2854116)
TT 102 (45.7 %) 75 (35.7 %) Ref
TC 101 (45.3 %) 97 (46.2 %) 0.199 1.306 0.868 ~ 1.965
CC 20 (9.0 %) 38 (18.1 %) 0.002 2.584 1.392 ~ 4.795
TT 102 (45.7 %) 75 (35.7 %) Ref
TC + CC 121 (54.3 %) 135 (64.3 %) 0.034 1.517 1.031 ~ 2.233
T 305 (68.4 %) 247 (58.8 %) Ref
C 141 (31.6 %) 173 (41.2 %) 0.003 1.515 1.147 ~ 2.002
SNP single nucleotide polymorphis
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Fig. 2 Forest plots showing the correlations between apolipoprotein A5 (APOA5) -1131 T > C (rs662799) single nucleotide polymorphisms (SNPs)
and coronary heart disease (a: allele model; b: dominant model)
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as means ± standard deviation, which was further exam-
ined with the use of t test, while quantitative data were
shown as percent, which also further analyzed by chi-
square test. In order to analyze deviation from the Hardy-
Weinberg equilibrium, the observed and expected frequen-
cies of genotype were compared with the utilization of chi-
square test. Odds ratio (OR) with 95 % confidence interval
(CI) were calculated to evaluate differences of genotype
and allele frequencies between case and control groups.
Two-tailed P values of < 0.05 were statistically significant.
With regard to data analyses in the following meta-
analysis, STATA 12.0 software (Stata Corp, College Station,
TX, USA) was used. OR with 95 % CI in fixed-effect model
or random-effect model, presented in forest plot, was cal-
culated to assess the strength of the association of CHD
with APOA5 -1131 T > C and APOC3 -455 T >C, whose
overall estimates were examined by Z test [28].Results
Clinical data and biochemical index
There was no significant difference on age and sex be-
tween case and control group (P > 0.05). History of
smoking, drinking, hypertension and diabetes mellitus,
and levels of TG and FBS, and body mass index (BMI)
in case group were shown to be higher than control
group (P < 0.05), while levels of TC, HDL-C and LDL-C
in case group were lower than control group (P < 0.05)
(Table 2).
Distribution of APOA5 -1131 T > C and APOC3 -455 T > C
SNPs
Distribution frequencies of genotypes of both APOA5
-1131 T > C and APOC3 -455 T > C SNPs complied with
Hardy-Weinberg equilibrium in case and control groups
(all P > 0.05), which indicated that this two SNPs were
shown to be representative in this population. As
Fig. 3 Forest plots showing the correlations between apolipoprotein C3 (APOC3) -455 T > C (rs2854116) single nucleotide polymorphisms (SNPs)
and coronary heart disease (a: allele model; b: dominant model)
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of APOA5 -1131 T > C and APOC3 -455 T > C in case
group were higher compared to control group (both P
< 0.05). Additionally, T allele frequencies of the two
SNPs in case group were lower than control group,
while C allele in case group has higher frequencies
compared to control group (both P < 0.05).Meta-analysis results
Our meta-analysis enrolled a total of 11 case–control
study [24, 29–38] including 4840 CHD patients and
4913 health individuals. The results, pooled from 9
studies reporting the association between CHD and
APOA5 -1131 T > C, suggested that under allele model
and dominant gene model -1131 T > C SNP is likely to
increase the risk of CHD (allele model (C compared to
T): OR = 1.65, 95 % CI = 1.53 ~ 1.79, P < 0.001, Fig. 2a;
dominant model (TC+ CC compared to TT): OR =
1.55, 95 % CI = 1.17 ~ 2.06, P = 0.003, Fig. 2b). There
were 3 studies that reported the association between CHD
and APOC3 -455 T >C and meta-analysis results indicated
that under allele model and dominant gene model -455 T >
C SNP had potential to increase the risk of CHD (allele:
OR = 0.64, 95 % CI = 0.51 ~ 0.80, P < 0.001, Fig. 3a; domin-
ant: OR = 0.57, 95 % CI = 0.43 ~ 0.75, P < 0.001, Fig. 3b).Discussion
The presented study evaluated the correlations of
CHD with APOA5 -1131 T > C and APOC3 -455 T > C
SNPs. Furthermore, in order to obtain a more conclu-
sive and definitive estimation of the correlation of
CHD with the two SNPs, our new case–control study
combined with a meta-analysis pooled results from
previously published studies were systematically car-
ried out. The overall results of our study suggested
that there was a strong link between the two SNPs,
APOA5 -1131 T > C and APOC3 -455 T > C, with in-
creased risk of CHD.
CHD, also known as coronary artery disease, is a
multifactorial disorder, the risk of which was involved
with some plasma lipids such as TC as well as TG,
LDL-C, and HDL cholesterol (HDL-C), and lifestyles
including smoking, alcohol consumption [39]. Add-
itionally, both hypertension and diabetes mellitus were
also involved in the development and progression of
CHD [40]. In our study, we compared the clinical data
and biochemical indexes of subjects between CHD
patients and health individual, and the results demon-
strated that CHD patients had longer history of smok-
ing, drinking, hypertension along with diabetes
mellitus, and lower levels of TC, HDL-C and LDL-C
compared to health individuals.
Yang et al. Lipids in Health and Disease  (2015) 14:113 Page 7 of 8One of our results in our study was that APOA5
-1131 T >C SNP is likely to increase the risk of CHD,
which was further demonstrated by the following meta-
analysis. APOA5, encoding apolipoprotein AV, is expressed
in the liver and circulates on very low density lipoproteins,
chylomicrons CM and HDL [41]. Apolipoprotein AV
participates in the catabolism of triglyceride-rich particles
by exerting the activation of lipoprotein lipase, leading to
the promotion of TG hydrolysis [29]. The rare haplotype
in vivo would result in the reduction of apolipoprotein AV
synthesis, and thus there was less apolipoprotein AV that
was available for incorporation into triglyceride-rich parti-
cles, with the consequence of less circulating apolipoprotein
AV to promote the activation of lipoprotein lipase or to
affect its receptor-mediated clearance, eventually develop-
ing atherosclerosis [10, 42]. In our study, CC and TC +CC
frequencies of APOA5 -1131 T > C were higher compared
to health individuals. Consist with our results, Sarwar
et al. reported that the -1131 T > C (rs662799) promoter
polymorphism of the APOA5 gene was related to higher
VLDL concentration as well as smaller HDL particle size
pathways by which triglyceride could exert influence on
the risk of CHD [10].
Another results in the current study suggested that
APOC3 -455 T >C had potential to increase the risk of
CHD, which also further demonstrated by our meta-
analysis. The metabolism of circulating particles rich in
TGs is closely influenced by their content in APOC3
encoded by APOC3 gene, and it is a component that inter-
feres with the lipoprotein lipase-triggered hydrolysis of
these particles [21]. The APOC3 gene is transcriptionally
down-regulated through insulin levels, and sequences in
the promoter region with high adherence for the nuclear
transcription factors inducing the insulin response are
highly polymorphic [43]. Variants at positions −455 in
APOC3 gene have been shown to have a decreased affinity
for the nuclear transcription factors inducing the response,
which is also relevant to a half of insulin-generated down-
regulation of APOC3 gene expression [44]. APOC3 is an
important inhibitor of the lipolysis of triglyceride-rich lipo-
proteins via countering APOC2 activation of lipoprotein
lipase [45]. Interestingly, Hypertriglyceridemia has been ac-
cepted by the National Cholesterol Education Program
Adult Treatment Panel III as a potent risk factor for the
development and progression of CHD [46].
In conclusion, our study demonstrated that APOA5
-1131 T > C and APOC3 -455 T > C SNPs may play po-
tent roles in the development and progression of CHD.
On a more practical ground, further researches with lar-
ger sample size are needed to examine whether incorp-
oration of the APOA5 -1131 T > C and APOC3 -455 T >
C SNPs into a general algorithm including genetic and
metabolic variables will help further improving the iden-
tification of individuals at early risk of CHD.Competing interests
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